Page 10 - Research Comment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate announcements from Aves One AG, Original-Research: Aves One AG (von GBC AG): under review

^ Original-Research: Aves One AG - von GBC AG Einstufung von GBC AG zu Aves One AG Unternehmen: Aves One AG ISIN: DE000A168114 Anlass der Studie: Research Comment Empfehlung: under review Kursziel: under review Letzte Ratingänderung: Analyst: Cosmin Filker, Matthias Greiffenberger Takeover offer...

Original-Research: Vectron Systems AG (von GBC AG): Buy vom 30.07.2021, 09:31 Uhr Bild: pixabay.com Einstufung von GBC AG zu Vectron Systems AG Unternehmen: Vectron Systems AG Empfehlung: Buy Letzte Ratingänderung: 1H 2021: New record figures for sales and earnings achieved, 2021 forecasts slightly increased, target price: EUR21.55; rating: BUY On 20 July 2021 Vectron Systems AG (short: Vectron) published extraordinarily good preliminary figures for the second quarter 2021 and thus for the first half-year 2021. After an increase in sales of +14.7% to EUR 8.6 million in the first quarter of ...

Letzte Ratingänderung: Analyst: Cosmin Filker, Felix Haugg 1H 2021: New record figures for sales and earnings achieved, 2021 forecasts slightly increased, target price: EUR21.55; rating: BUY On 20 July 2021 Vectron Systems AG (short: Vectron) published extraordinarily good preliminary figures for the second quarter 2021 and thus for the first half-year 2021. After an increase in sales of +14.7% to EUR 8.6 million in the first quarter of 2021, sales more than doubled to EUR 12.5 million in the second quarter of 2021 (Q2 2020: EUR 5.1 million), thus marking a new quarterly record. Vectron also...

Letzte Ratingänderung: Analyst: Cosmin Filker, Marcel Goldmann Further results of the pivotal study 2a confirm expectations, market approval in 2021 still in prospect, price target of EUR 11.00 and BUY rating confirmed After MagForce AG announced the successful completion of stage 2a of the pivotal study for the treatment of prostate cancer in the USA in February 2021, the company has published additional, more concrete results on this study phase in a recent company announcement. After further analysis of the results of the 10 patients included in phase 2a, only minimal side effects were ob...